Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Norethynodrel (also spelled noretynodrel) is a synthetic progestin, structurally related to 19-nortestosterone, and was the progestin component of the first marketed oral contraceptive. It was primarily used in combination with the estrogen mestranol for contraception and in the treatment of gynecological disorders such as functional uterine bleeding and endometriosis. Norethynodrel acts as a progestogen agonist with very weak estrogenic activity. Due to its rapid metabolism and low receptor affinity, it is considered a prodrug that is quickly converted into active metabolites after oral administration—possibly including norethisterone—though this remains debated. The drug has been discontinued and is no longer marketed or used medically[1][2][4][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on norethynodrel.